MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
about
Recent advances in the development of Aurora kinases inhibitors in hematological malignanciesInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsA phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.Chronic myeloid leukemia: overview of new agents and comparative analysis.Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).Bcr-Abl tyrosine kinase inhibitors: a patent review.Synthesis and Evaluation of New Pyrazoline Derivatives as Potential Anticancer Agents in HepG-2 Cell Line.The Aurora kinase inhibitors in cancer research and therapy.Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cPast, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
P2860
Q26775723-5EBBC3C7-C260-4CAF-8556-B1D66F4DFEC0Q28545195-18C44BB6-D9E3-451E-9102-913FE130C8C3Q34448958-BC6F5D9D-20F3-4252-9702-5CE145E7553BQ37013275-56B6CD44-283F-4810-9467-58BD18AEBD89Q38097728-BC499E7F-32B2-4743-8F08-F13C46E35691Q38223271-39DA5EC5-502D-407D-8980-32C07FA92E71Q38345974-F70E5436-7ADC-41D7-8E38-7EC0A2FDAC03Q38712052-FFE4F572-E527-4083-ADF0-E20C51E66577Q38756932-4D3EA9BF-BBBF-4582-A9A9-39449B275DE9Q38796480-BAB0835D-0C6C-4127-8EFD-F330D051F4A5Q38845834-6E8355D9-21C1-4E45-9276-F3835474A410Q47339376-E9E1656C-D72B-4AC0-9166-2515AE08FD63Q49025576-6AF4581E-F6A2-4336-9196-38A1361B4AA8Q49887884-F0B7C4A7-0629-4F18-87AB-90ABDF4C6607Q54303287-D35FFDFB-2D3C-453E-9A47-D394F0F1CFA3Q55362356-DB16423D-6656-432F-84C2-6AB1067411F5
P2860
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
MK-0457, an Aurora kinase and ...... s with BCR-ABL T315I leukemia.
@en
MK-0457, an Aurora kinase and ...... s with BCR-ABL T315I leukemia.
@nl
type
label
MK-0457, an Aurora kinase and ...... s with BCR-ABL T315I leukemia.
@en
MK-0457, an Aurora kinase and ...... s with BCR-ABL T315I leukemia.
@nl
prefLabel
MK-0457, an Aurora kinase and ...... s with BCR-ABL T315I leukemia.
@en
MK-0457, an Aurora kinase and ...... s with BCR-ABL T315I leukemia.
@nl
P2093
P2860
P356
P1433
P1476
MK-0457, an Aurora kinase and ...... s with BCR-ABL T315I leukemia.
@en
P2093
D A Rizzieri
D Bergstrom
J E Cortes
P D Le Coutre
P2860
P2888
P304
P356
10.1038/LEU.2012.186
P577
2012-07-09T00:00:00Z